CHICAGO—Are effective treatments for osteoarthritis (OA) on the horizon? In Emerging Treatments for Osteoarthritis at the 2018 ACR/ARHP Annual Meeting, experts discussed potential therapies to address OA structural progression, pain and inflammation.
With an aging population and rising obesity rates, “we can expect the prevalence of osteoarthritis will only increase,” said Anne-Marie Malfait, MD, PhD, George W. Stuppy Chair of Arthritis at Rush University Medical Center, Chicago. OA involves failure of joint cartilage, bone and synovial tissue, “but for the patient, what is important is loss of function of the joint and also, very importantly, pain.”1
Several disease-modifying anti-osteoarthritis drugs (DMOADs) are in development. DMOADs inhibit structural progression and, hopefully, improve pain and function.
‘Another challenge is that the mean time of this disease is about 20 years. We tend to focus on the past two years.’ —David Hunter, MBBS, PhD